Nimodipin Carinopharm (Nimodipine)

Nimodipine selectively inhibits L‑type voltage‑gated calcium channels in the smooth muscle of cerebral arteries. This blockade reduces calcium entry, causing relaxation of the vascular smooth muscle, which leads to cerebral vasodilation and increased cerebral perfusion without markedly affecting systemic blood pressure.

The dosing regimen for Nimodipin Carinopharm is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals set the infusion rate and duration according to established guidelines for subarachnoid hemorrhage management.

Safety data for nimodipine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate individual circumstances and discuss possible risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nimodipine is unique among calcium channel blockers for its high affinity for cerebral vessels, providing targeted vasodilation with minimal systemic effects. Compared with non‑selective vasodilators, it offers a better safety profile for managing vasospasm after subarachnoid hemorrhage, though individual response may vary.

Store the product at temperatures below 25 °C, in its original container, protected from moisture and light. Do not freeze. Before use, inspect the solution for particulate matter or discoloration and ensure aseptic handling according to standard intravenous preparation protocols.

Nimodipin Carinopharm is administered intravenously. The solution is typically infused over a prescribed period, often as a continuous infusion, under close hemodynamic monitoring. Administration techniques follow institutional protocols for sterile IV drug delivery.

Serious risks include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as anaphylaxis, and rare occurrences of seizures or pulmonary edema. Prompt recognition and management of these events are essential, and patients should be monitored closely during therapy.

Patients with known hypersensitivity to nimodipine or any component of the formulation should avoid its use. Caution is advised in individuals with severe hypotension, significant cardiac disease, or hepatic impairment. The drug is contraindicated when co‑administered with strong CYP3A4 inhibitors that cannot be discontinued.